Tempest Therapeutics, Inc.
TPST- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001544227
No open-market purchases or sales by Tempest Therapeutics, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $1.44M in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Tempest Therapeutics, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 17 | 22 | +5 |
| Shares | 3.11M | 3.83M | +717.6K (+23.1%) |
| Value | $7.21M | $4.86M | −$2.35M (−32.6%) |
New holders (7)
Institutions that held Tempest Therapeutics, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| AIGH Capital Management LLC | 406,250 | $515.9K | 0.21% |
| Sectoral Asset Management Inc | 219,394 | $278.6K | 0.05% |
| Worth Venture Partners, LLC | 101,550 | $129.0K | 0.07% |
| Two Sigma Investments, LP | 15,977 | $20.3K | 0.00% |
| Two Sigma Securities, LLC | 14,555 | $18.5K | 0.00% |
| UBS Group AG | 800 | $1.02K | 0.00% |
| Whittier Trust Co | 13 | $15 | 0.00% |
Sold out (2)
Institutions that held Tempest Therapeutics, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Susquehanna International Group, LLP | 11,087 | $25.7K |
| JPMorgan Chase & Co | 313 | $1.00K |